Regulatory Information
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
Therapeutic
Prescription Only
Formulation Information
TABLET
**Dosage:** Oral administration. It is usually given in a dose range of 5 to 60mg daily, in divided doses or as a single daily dose at 8am or as a double dose on alternate days. In long term therapy, dosage should be maintained at not more than about 7mg daily whenever possible as side effects inevitably occur with higher dosage.
ORAL
Medical Information
**Indications:** It is indicated for primary or secondary adrenocortical insufficiency, rheumatic disorders, collagen diseases (systemic lupus erythematosus), dermatologic diseases (pemphigus, severe psoriasis, severe seborrheic dermatitis), bronchial asthma, ophthalmic diseases (eye inflammation, herpes zoster ophthalmicus, allergic conjunctivitis), hematologic disorders, neoplastic diseases (leukemia), edematous states and gastrointestinal diseases (ulcerative colitis).
**Contraindications:** It is contraindicated in systemic fungal infection and hypersensitivity to any component of the product.
H02AB06
prednisolone
Manufacturer Information
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
SUNWARD PHARMACEUTICAL PRIVATE LIMITED
Active Ingredients
Documents
Package Inserts
DELTASOLONE TABLET 5 mg PI.pdf
Approved: May 17, 2023